Industry analysts are insisting that new weight loss and diabetes drugs like Ozempic won't hurt the demand for insulin pumps and continuous glucose monitors, but most investors aren't buying it.
The answer may depend on who you listen to and whether you see GLP-1 drugs as a help or a hinderance to the category.
DXCM 3M mountain In the quarter to date, Dexcom shares are down nearly 19%.
Dexcom shares are down more than 7% year to date.
TNDM 3M mountain Tandem Diabetes shares have fallen significantly this year.
Persons:
Ozempic, Danielle Antalffy, Eli Lilly's Mounjaro, hasn't, Dexcom, Piper Sandler, Matt O'Brien, O'Brien, Paresh Dandona, semaglutide, Travis Steed, Steed, — CNBC's Michael Bloom
Organizations:
UBS, Nordisk's, Novo, New, of Medicine, Tandem Diabetes, Tandem Diabetes Care, Diabetes, Jacobs School of Medicine, Biomedical Sciences, University of Buffalo, Novo Nordisk's, Bank of America
Locations:
CGMs